immuno-oncology

News

Takeda buys GammaDelta to boost cancer cell therapy credenti...

Japanese drugmaker Takeda has said it will exercise its option to buy UK-based GammaDelta Therapeutics, a specialist in 'off-the-shelf' cell therapies for solid tumours and blood cancers.

News

AZ/Daiichi partner with Merck on first-line lung cancer tria...

The dominance of Merck & Co's Keytruda in the treatment of previously-untreated non-small cell lung cancer (NSCLC) means it will be hard to dislodge – so AstraZeneca and Daiichi Sankyo

News

AZ's Imfinzi is first immunotherapy to raise survival in bil...

AstraZeneca's checkpoint inhibitor Imfinzi has become the first cancer immunotherapy to improve survival in previously-untreated patients with biliary tract cancer (BTC), a rare and aggress

News

Merck gets EU approval for Keytruda in triple-negative breas...

Merck & Co has claimed EU approval for Keytruda in triple-negative breast cancer (TNBC), a particularly hard-to-treat form of the disease.

News

BMS strikes back against Merck in EU oesophageal cancer mark...

Merck & Co's Keytruda become the first cancer immunotherapy to be approved as a first-line oesophageal cancer treatment in the EU earlier this year, but will now face competition from B

News